Constipation News and Research

Latest Constipation News and Research

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.

7 May 2010

Columbia Laboratories reports 34% increase in net revenues from U.S. sales of progesterone products

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2010.

6 May 2010

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Labopharm Inc. today reported its financial results for the first quarter 2010.

6 May 2010

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

A targeted antibiotic provides effective and long-lasting relief of Irritable Bowel Syndrome symptoms, according to the results of two multisite Phase III clinical trials designed by Cedars-Sinai researchers. Rifaximin is the first drug treatment for IBS that relieves symptoms while it's being administered and continues to benefit patients after they stop taking the drug.

5 May 2010

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Alvine Pharmaceuticals, Inc., today announced the reporting of scientific data on the performance of its lead compound, ALV003, in a gastric simulation model. The data were presented at the 2010 Digestive Disease Week (DDW) meeting held in New Orleans, Louisiana.

5 May 2010

Mayo Clinic researchers identify genetic variants in serotonin genes that impact IBS

Most people associate serotonin with brain neurology, but over 95 percent of the body's serotonin occurs in the gastrointestinal tract, which has a complex neuronal circuit that has been called "the second brain" of the body.

5 May 2010

UCSF transgenic mouse model first to display earliest signs of Parkinson's disease

UCSF researchers have created the first transgenic mouse to display the earliest signs of Parkinson's disease using the genetic mutation that is known to accompany human forms of the disease.

4 May 2010

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Sucampo Pharmaceuticals, Inc. today presented results of a phase 2 clinical trial of cobiprostone, an investigational drug, for the prevention of gastric ulcers and other gastrointestinal injuries in patients treated with non-steroidal anti-inflammatory drugs (NSAIDs). These data were presented at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, as part of the distinguished abstract plenary session.

4 May 2010

Researchers find better way to prep patients for colonoscopy procedures

Researchers at Henry Ford Hospital may have found a better way to prep patients for colonoscopy procedures so they no longer need to drink a gallon of prescribed fluids prior to the procedure.

3 May 2010

ATN study shows prevalence of GI symptoms in children with ASD

Parents of children and adolescents with autism spectrum disorders sometimes report that their children suffer from gastrointestinal symptoms, such as diarrhea and constipation. However, studies on how prevalent these symptoms are have had conflicting results.

3 May 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.

29 Apr 2010

Anytime Fitness expands across the Atlantic Ocean into the UK and Ireland

Anytime Fitness, the fastest-growing fitness club chain in the world, is showing no signs of slowing down. After opening more than 300 new clubs in the U.S. each of the past two years, the worldwide leader in neighborhood fitness clubs is expanding once again – this time across the Atlantic Ocean into the United Kingdom and Ireland.

29 Apr 2010

$Ageing population prone to bone fractures drives South African joint replacement market$

Ageing population prone to bone fractures drives South African joint replacement market

The joint replacement market in South Africa is set to experience continued growth in the medium to long term, driven by an ageing population that is prone to cartilage degeneration and bone fractures. The introduction of innovative products with enhanced durability and longevity as well as safer operation techniques is further boosting growth in this market.

29 Apr 2010

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans, US.

29 Apr 2010

IBS patients treated with cognitive behavior therapy have positive response: Study

A significant proportion of irritable bowel syndrome patients treated with cognitive behavior therapy have a positive response within four weeks of treatment, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

27 Apr 2010

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Cumberland Pharmaceuticals Inc. today announced that results from a patient preference study evaluating Kristalose (lactulose) for Oral Solution, a prescription laxative packaged as a crystalline powder, will be presented at the 2010 Digestive Disease Week meeting in New Orleans.

27 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Columbia Laboratories' net revenues from US progesterone sales for first-quarter up 36%

Columbia Laboratories, Inc. today announced preliminary results for the quarter ended March 31, 2010.

22 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Constipation News and Research

Latest Constipation News and Research

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

Columbia Laboratories reports 34% increase in net revenues from U.S. sales of progesterone products

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Targeted antibiotics provide safe, long-lasting improvement for IBS patients, says study

Alvine Pharmaceuticals reports data of ALV003 in gastric simulation model at DDW 2010

Mayo Clinic researchers identify genetic variants in serotonin genes that impact IBS

UCSF transgenic mouse model first to display earliest signs of Parkinson's disease

Sucampo Pharmaceuticals presents Phase 2 cobiprostone clinical trial data at DDW 2010

Researchers find better way to prep patients for colonoscopy procedures

ATN study shows prevalence of GI symptoms in children with ASD

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Anytime Fitness expands across the Atlantic Ocean into the UK and Ireland

Ageing population prone to bone fractures drives South African joint replacement market

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

IBS patients treated with cognitive behavior therapy have positive response: Study

Patient preference study results of Kristalose to be presented at 2010 Digestive Disease Week meeting

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Columbia Laboratories' net revenues from US progesterone sales for first-quarter up 36%

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Constipation News and Research

Latest Constipation News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in